NCT03355820View on ClinicalTrials.gov

A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study

PHASE3CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

June 29, 2018

Study Completion Date

June 29, 2018

Conditions
Cervical Intraepithelial Neoplasia
Interventions
PROCEDURE

Blood sampling for antibody determination

In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (\~5 mL) will be taken from all the subjects, at Day 1.

Trial Locations (1)

225300

GSK Investigational Site, Taizhou

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03355820 - A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study | Biotech Hunter | Biotech Hunter